Oragenics (OGEN) is currently developing a next generation COVID vaccine, focused on the creation of the TerraCoV2 immunization product candidate, getting closer toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria.
The company announced that it has entered into a licensure agreement with the National Research Council of Canada for rapid development of a next generation COVID vaccine in addition to its variants.
In combination with the U.S. NIH it will allow Oragenics to generate cell lines within six to eight weeks of spike gene sequence availability compared to six to nine months in traditional production.
With respect to our potential future competitive positioning against currently available SARS-CoV-2 vaccines, we believe the licensed technologies will improve development speed, while the ability to rapidly engineer new vaccine antigens will permit us to quickly address new variants as they arise. In addition, our agreement with Biodextris for an intranasal adjuvant is expected to complement our intramuscular administration options and should position Oragenics with several antigen-adjuvant options in the event that SARS-CoV-2 become a seasonal flu-like disease, as many experts anticipate will be the case.
Frederick W. Telling, Executive Chairman at Oragenics
